World Anti-obesity Drugs Market to Reach $6.9 Billion by 2015, According to New Report by Global Industry Analysts Inc.

Share Article

Driven by growth in obesity prevalence and launch of emerging therapies in development, world market for anti-obesity drugs is projected to reach $6.9 billion by the year 2015. Obesity prevalence translates to wider opportunities for drug companies, as there exists a huge market for highly efficacious and novel drugs. As such, major proportion of currently available drugs does not meet existing requirements for safety profile and efficacy.

Anti-obesity Drugs: A Global Strategic Business Report

The world today is facing an acute crisis of over-weightiness and its more advance form, obesity. The need to combat obesity may be understood from the fact that it gives rise to life threatening ailments such as heart attack, hypertension, diabetes and certain types of cancer.

The United States and Europe dominates the world anti-obesity drugs market as stated by a recent report published by Global Industry Analysts, Inc. There has been significant rise in number of obese people in recent times, particularly in three major regions namely, the US, Europe and Japan. The US is home to the majority of world's obese population and the number is still on rise. Therapies for obesity and associated diseases account for a substantial chunk of the overall healthcare expenditure in the US. Within Europe, Germany is the largest market for anti-obesity drugs. Other developing nations including China, India, Brazil and Russia are also expected to contribute to market growth.

Though there exists significant potential for obesity therapeutics, the market continues to face challenges that could hinder the growth momentum. In recent times, withdrawal of certain drugs and discontinuation of pipeline drugs by certain pharmaceutical majors caused a dent in market prospects. Acomplia (rimonabant), an anti-obesity drug from Sanofi-Aventis was suspended by EMEA in 2008 following reports of psychiatric disorders in patients. Additionally, safety concerns and inconvenient injectible formulation of the drugs also pose barrier to market growth.

Leading global and regional players dominating the market include Abbott Laboratories, Alizyme Plc, Amylin Pharmaceuticals, Inc., AstraZeneca Plc, F.HOFFMANN-LA ROCHE LTD., GlaxoSmithKline Plc, Sanofi-Aventis SA, SuperGen Inc., Takeda Pharmaceutical Company Limited and VIVUS, Inc., among others

The report titled "Anti-obesity Drugs: A Global Strategic Business Report" published by Global Industry Analysts, Inc., covers major market dynamics, trends, issues, and competition pertaining to the market. The report enumerates recent product introductions/innovations, developments, clinical trials, and mergers, acquisitions and other strategic industry activities. Analysis is presented for the period 2005-2015 for markets including The United States, Europe, France, Germany, Italy, UK, and Rest of World.

For more details about this research report, please visit http://www.strategyr.com/Anti_Obesity_Drugs_Market_Report.asp.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press (at) StrategyR (dot) com
Web Site http://www.StrategyR.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website